TET2‑mediated5hmC as a transcriptional rheostat that tempers SASP in senescent T cells

Hypothesis: Senescent T cells employ TET2-mediated 5-hydroxymethylcytosine (5hmC) deposition within the gene bodies of SASP components as a transcriptional rheostat that limits the amplitude and heterogeneity of inflammatory signaling, thereby preserving tissue homeostasis. In aging, declining TET activity reduces this brake, allowing SASP to become hyper‑reactive and driving inflammaging. Senolytic agents that inadvertently lower TET2 (e.g., ABT‑737) may remove senescent cells but also eliminate this protective 5hmC‑mediated damping, potentially unleashing a secondary wave of inflammation from neighboring cells or from residual senescent precursors.

Specific predictions:

1. In purified senescent CD4+ T cells from old mice, 5hmC levels will be significantly elevated at the gene bodies of canonical SASP genes (Il6, Il1b, Ccl3, Cxcl10) compared with non‑senescent naïve or effector counterparts.
2. CRISPR‑mediated knockout of Tet2 in senescent T cells will increase nascent transcription (measured by EU‑labeling or PRO‑seq) and secretory output of SASP cytokines without affecting cell viability.
3. Conversely, overexpression of a catalytically active TET2 in senescent T cells will reduce 5mC, increase 5hmC at those loci, and dampen SASP secretion, an effect that requires the 5hmC‑reader MBD3/NURD complex (shown by MBD3 knockdown rescuing the phenotype).
4. In vivo, treating aged mice with ABT‑737 will clear senescent T cells but concomitantly reduce Tet2 expression and 5hmC at SASP loci in the remaining T‑cell compartment; administering a TET2 activator (e.g., vitamin C) alongside ABT‑737 will preserve 5hmC levels and prevent the secondary inflammatory surge observed after senolytic monotherapy.
5. If the rheostat model is false, Tet2 loss or gain will not alter SASP magnitude, and 5hmC will not be enriched at SASP gene bodies in senescent T cells.

Experiments to falsify:

• Perform hMeDIP‑seq or oxidative bisulfite sequencing on FACS‑sorted senescent (CD44^high CD62L^low p16^high) vs non‑senescent CD4+ T cells from 20‑month‑old mice; lack of 5hmC enrichment at SASP loci refutes prediction 1.
• Use Tet2‑fl/fl × Cd4‑Cre ERT2 mice to delete Tet2 specifically in T cells after senescence induction (e.g., via irradiation) and measure SASP; unchanged SASP levels falsify predictions 2‑3.
• Administer ABT‑737 ± vitamin C to aged mice and assay serum IL‑6, CXCL10, and tissue histology; a failure of vitamin C to mitigate post‑senolytic inflammation falsifies prediction 4.

This hypothesis reframes senescent cells not as passive sources of damage but as active regulators that use TET2‑driven 5hmC to fine‑tune their own secretory phenotype, providing a mechanistic basis for the observed TET2 downregulation after senolytic treatment and suggesting combinatorial strategies that preserve the brakes while removing the cells.